Top

Published in:

Open Access 01-06-2016 | Review Article

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Authors: Jeffrey C. Bryan, Srdan Verstovsek

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2016

Abstract

Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative neoplasms associated with somatic hematopoietic stem cell mutations leading to over activation of JAK–STAT signaling. MF and PV are pathogenically related and share specific clinical features such as splenomegaly and constitutional symptoms. The MF phenotype is dominated by the effects of progressive bone marrow fibrosis resulting in shortened survival. In contrast, elevated thrombosis risk due to erythrocytosis is the primary clinical concern in PV. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is approved in the USA for the treatment of patients with intermediate- or high-risk MF and patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. For MF, results of two phase III studies demonstrated that ruxolitinib therapy reduced spleen volume and MF-related symptom burden, improved quality-of-life measures, and was associated with prolonged overall survival. Treatment benefits were generally sustained with continued therapy. Dose-dependent cytopenias were common but generally manageable with transfusions (for anemia), dose reduction, or treatment interruption. Optimal dosing management is critical to maintain long-term treatment benefit, because cessation of therapy resulted in rapid return of symptoms to baseline levels. Results of the phase III PV trial showed that ruxolitinib was significantly more effective than standard therapy in controlling hematocrit levels and improving splenomegaly and PV-related symptoms. Only 1 of 110 patients in the ruxolitinib arm compared with 6 of 112 patients in the control arm experienced a thromboembolic event through week 32. Grade ≥3 cytopenias were uncommon.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397. doi:10.1016/j.ccr.2005.03.023 PubMedCrossRef

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790. doi:10.1056/NEJMoa051113 PubMedCrossRef

Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C (2014) Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 99:292–298. doi:10.3324/haematol.2013.087650 PubMedPubMedCentralCrossRef

Cross NC (2011) Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011:208–214. doi:10.1182/asheducation-2011.1.208 PubMed

Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, Kilpivaara O, Wadleigh M, Busque L, Gilliland DG, Golub TR, Ebert BL, Levine RL (2014) Integrated genomic analysis illustrates the central role of JAK–STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123:e123–e133. doi:10.1182/blood-2014-02-554634 PubMedPubMedCentralCrossRef

Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10:127–140. doi:10.1038/nrd3264 PubMedCrossRef

Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, on behalf of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:437–438. doi:10.1038/sj.leu.2404914 PubMedCrossRef

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951. doi:10.1182/blood-2009-03-209262 PubMedCrossRef

Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118:1723–1735. doi:10.1182/blood-2011-02-292102 PubMedCrossRef

10.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant’Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390. doi:10.1056/NEJMoa1311347 PubMedCrossRef

11.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O’Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405. doi:10.1056/NEJMoa1312542 PubMedPubMedCentralCrossRef

12.

Savona MR (2014) Are we altering the natural history of primary myelofibrosis? Leuk Res 38:1004–1012. doi:10.1016/j.leukres.2014.04.012 PubMedCrossRef

13.

Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220–2228. doi:10.1182/blood-2013-11-537167 PubMedCrossRef

14.

Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124:2507–2513; quiz 2615. doi:10.1182/blood-2014-05-579136 PubMedPubMedCentralCrossRef

15.

Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861–1869. doi:10.1038/leu.2013.119 PubMedCrossRef

16.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117–1127. doi:10.1056/NEJMoa1002028 PubMedCrossRef

17.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL (2015) JAK–STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 5:316–331. doi:10.1158/2159-8290.CD-14-0736 PubMedPubMedCentralCrossRef

18.

Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109–3117. doi:10.1182/blood-2009-04-214957 PubMedPubMedCentralCrossRef

19.

Geyer HL, Mesa RA (2014) Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 124:3529–3537. doi:10.1182/blood-2014-05-577635 PubMedCrossRef

20.

Jakafi (ruxolitinib) tablets [prescribing information] (2014). Incyte Corporation, Wilmington, DE

21.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807. doi:10.1056/NEJMoa1110557 PubMedPubMedCentralCrossRef

22.

Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51:1644–1654. doi:10.1177/0091270010389469 PubMedCrossRef

23.

Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, Shepard S, Rodgers J, Yue TY, Yeleswaram S (2010) Metabolism, excretion, and pharmacokinetics of [¹⁴C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos 38:2023–2031. doi:10.1124/dmd.110.033787 PubMedCrossRef

24.

Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52:809–818. doi:10.1177/0091270011405663 PubMedCrossRef

25.

Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87:25–33. doi:10.1016/j.mayocp.2011.11.001 PubMedPubMedCentralCrossRef

26.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A (2011) Philadelphia–negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770. doi:10.1200/JCO.2010.31.8436 PubMedCrossRef

27.

Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265. doi:10.1056/NEJM200004273421706 PubMedCrossRef

28.

Le Bousse-Kerdilès MC, Martyré MC, Samson M (2008) Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 19:69–80. doi:10.1684/ecn.2008.0127 PubMed

29.

Hasselbalch HC (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 24:133–145. doi:10.1016/j.cytogfr.2013.01.004 PubMedCrossRef

30.

Abdel-Wahab OI, Levine RL (2009) Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 60:233–245. doi:10.1146/annurev.med.60.041707.160528 PubMedCrossRef

31.

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118:401–408. doi:10.1182/blood-2011-01-328955 PubMedCrossRef

32.

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901. doi:10.1182/blood-2008-07-170449 PubMedCrossRef

33.

Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392–397. doi:10.1200/JCO.2010.32.2446 PubMedCrossRef

34.

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703–1708. doi:10.1182/blood-2009-09-245837 PubMedCrossRef

35.

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109:68–76. doi:10.1002/cncr.22365 PubMedCrossRef

36.

Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S (2012) Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 120:2768–2769. doi:10.1182/blood-2012-07-446849 PubMedPubMedCentralCrossRef

37.

Mesa RA, Tefferi A (2001) Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma 42:901–911. doi:10.3109/10428190109097709 PubMedCrossRef

38.

Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 7:89–101. doi:10.2147/IJGM.S51800 PubMedPubMedCentral

39.

Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105:973–977. doi:10.1182/blood-2004-07-2864 PubMedCrossRef

40.

Rampal R, Mascarenhas J (2014) Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Curr Opin Hematol 21:65–71. doi:10.1097/MOH.0000000000000017 PubMedCrossRef

41.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98:1865–1871. doi:10.3324/haematol.2013.092155 PubMedPubMedCentralCrossRef

42.

Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, Belachew AA, Pancrazzi A, Wassie EA, Ketterling RP, Hanson CA, Pardanani A, Vannucchi AM (2014) CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 28:1494–1500. doi:10.1038/leu.2014.57 PubMedCrossRef

43.

Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K, Reiter A, Duncombe A, Fanelli T, Pietra D, Rumi E, Finke C, Gangat N, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NC, Vannucchi AM, Tefferi A (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28:1804–1810. doi:10.1038/leu.2014.76 PubMedCrossRef

44.

Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29:1356–1363. doi:10.1200/JCO.2010.32.9490 PubMedCrossRef

45.

Mesa RA, Schwager S, Huang J, Pardanani AD, Hussein K, Camoriano J, Tefferi A (2009) Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the pre JAK2 inhibitor era [abstract]. Blood (ASH Annu Meet Abstr) 114:3918

46.

Sulai N, Mengistu B, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Tefferi A (2012) Decreased levels of total or HDL cholesterol in primary myelofibrosis are associated with shortened survival: DIPSS-Plus independent prognostic value [abstract]. Blood (ASH Annu Meet Abstr) 120:2851

47.

Lekovic D, Gotic M, Perunicic-Jovanovic M, Vidovic A, Bogdanovic A, Jankovic G, Cokic V, Milic N (2014) Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol 31:869. doi:10.1007/s12032-014-0869-8 PubMedCrossRef

48.

Newberry KJ, Naqvi K, Nguyen KT, Cardenas-Turanzas M, Florencia Tanaka M, Pierce S, Verstovsek S (2014) Comorbidities predict worse prognosis in patients with primary myelofibrosis. Cancer 120:2996–3002. doi:10.1002/cncr.28857 PubMedPubMedCentralCrossRef

49.

Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, Savi F, Moro A, Grifoni F, De Philippis C, Radice T, Bosari S, Lambertenghi Deliliers G, Cortelezzi A (2012) The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 25:1193–1202. doi:10.1038/modpathol.2012.87 PubMedCrossRef

50.

Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka HM, Büsche G, Ayuk F, Bacher U, Zander AR, Kröger N (2012) Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 157:75–85. doi:10.1111/j.1365-2141.2011.09009.x PubMedCrossRef

51.

Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N (2014) Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 99:916–921. doi:10.3324/haematol.2013.094284 PubMedPubMedCentralCrossRef

52.

Gupta V, Hari P, Hoffman R (2012) Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 120:1367–1379. doi:10.1182/blood-2012-05-399048 PubMedCrossRef

53.

Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S (2014) Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38:1126–1129. doi:10.1016/j.leukres.2014.06.015 PubMedPubMedCentralCrossRef

54.

Daver N, Shastri A, Kadia T, Quintás-Cardama A, Jabbour E, Konopleva M, O’Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S (2013) Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37:1440–1444. doi:10.1016/j.leukres.2013.07.007 PubMedPubMedCentralCrossRef

55.

Burgstaller S, Fridrik M, Hojas S, Kuhr T, Ludwig H, Mayrbaurl B, Pohnl R, Potscher M, Schlogl E, Zauner D, Thaler J, Gisslinger H (2013) Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis. Wien Klin Wochenschr 125:196–199. doi:10.1007/s00508-013-0345-z PubMedCrossRef

56.

Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A (2012) Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 87:66–68. doi:10.1002/ajh.22233 PubMedCrossRef

57.

Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S (2011) Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 118:899–902. doi:10.1182/blood-2010-12-325589 PubMedPubMedCentralCrossRef

58.

Vannucchi AM (2011) Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011:222–230. doi:10.1182/asheducation-2011.1.222 PubMed

59.

Mesa RA, Tefferi A (2005) Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Semin Oncol 32:403–413. doi:10.1053/j.seminoncol.2005.04.012 PubMedCrossRef

60.

Rialon KL, Speicher PJ, Ceppa EP, Rendell VR, Vaslef SN, Beaven A, Tyler DS, Blazer DG 3rd (2015) Outcomes following splenectomy in patients with myeloid neoplasms. J Surg Oncol 111:389–395. doi:10.1002/jso.23846 PubMedCrossRef

61.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798. doi:10.1056/NEJMoa1110556 PubMedCrossRef

62.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100:479–488. doi:10.3324/haematol.2014.115840 PubMedPubMedCentralCrossRef

63.

Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, on behalf of the COMFORT-II investigators (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122:4047–4053. doi:10.1182/blood-2013-02-485888 PubMedCrossRef

64.

Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31:1285–1292. doi:10.1200/JCO.2012.44.4489 PubMedCrossRef

65.

Dueck AC, Cleeland CS, Dantzer R, Sloan J, Verstovsek S, M. ER, Geyer HL, Mesa RA (2013) Cytokine profile changes in 309 myelofibrosis patients: comparison of JAK1/JAK2 inhibitor therapy vs. placebo—correlative analysis from the COMFORT-I trial [abstract]. Blood 122:4074

66.

Squires M, Harrison CN, Barosi G, Vannucchi AM, Barbui T, Gisslinger B, Passamonti F, Al-Ali HK, Kiladijan JJ, Marker MT, Mendelson ET, Stalbovskaya V, Cervantes F, Knoops L (2013) The relationship between cytokine levels and symptoms in patients (Pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT) [abstract]. Blood 122:4070

67.

Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA (2014) Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123:3803–3810. doi:10.1182/blood-2013-09-527903 PubMedPubMedCentralCrossRef

68.

Hosoi M, Kumano K, Taoka K, Arai S, Kataoka K, Ueda K, Kamikubo Y, Takayama N, Otsu M, Eto K, Nakauchi H, Kurokawa M (2014) Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. Exp Hematol 42:816–825. doi:10.1016/j.exphem.2014.03.010 PubMedCrossRef

69.

Lu M, Xia L, Liu YC, Hochman T, Bizzari L, Aruch D, Lew J, Weinberg R, Goldberg JD, Hoffman R (2015) Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood. doi:10.1182/blood-2014-12-618595

70.

Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16:153–166. doi:10.1016/j.cmet.2012.06.011 PubMedCrossRef

71.

Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J (2015) Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk 15(214–221):e211. doi:10.1016/j.clml.2014.12.008

72.

Mascarenhas J, Hoffman R (2013) A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121:4832–4837. doi:10.1182/blood-2013-02-482232 PubMedCrossRef

73.

Cervantes F, Kiladjian J-J, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuity M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Gisslinger B, Vannucchi AM, Knoops L, Harrison CN (2012) Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [abstract]. Blood 120:801

74.

Cervantes F, Mesa R, Harrison C (2013) JAK inhibitors: beyond spleen and symptoms? Haematologica 98:160–162. doi:10.3324/haematol.2012.083543 PubMedPubMedCentralCrossRef

75.

Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM, on behalf of the COMFORT-II Investigators and the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators (2014) Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 123:2157–2160. doi:10.1182/blood-2013-11-536557 PubMedCrossRef

76.

Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 123:1833–1835. doi:10.1182/blood-2013-12-544411 PubMedCrossRef

77.

Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes JE, Kantarjian HM, Verstovsek S (2013) Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy [abstract]. Blood 122:4055

78.

Deininger M, Radich J, Burn T, Huber R, Paranagama D, Verstovsek S (2015) Ruxolitinib reduces JAK2p.V617F allele burden in patients with myelofibrosis [abstract P674]. Paper presented at the 20th Congress of the European Hematology Association, Vienna, Austria, June 11–14, 2015

79.

Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN (2013) Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 98:1872–1876. doi:10.3324/haematol.2013.095109 PubMedPubMedCentralCrossRef

80.

Molica M, Serrao A, Saracino R, Zacheo I, Stingone C, Alimena G, Breccia M (2014) Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? Ann Hematol 93:1951–1952. doi:10.1007/s00277-014-2096-y PubMedCrossRef

81.

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintás-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 7:13–21. doi:10.2147/OTT.S53348 PubMedPubMedCentralCrossRef

82.

Mesa RA, Cortes J (2013) Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol 6:79. doi:10.1186/1756-8722-6-79 PubMedPubMedCentralCrossRef

83.

Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O’Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6:81. doi:10.1186/1756-8722-6-81 PubMedPubMedCentralCrossRef

84.

Tabarroki A, Lindner D, Visconte V, Rogers HJ, Desamito J, Duong HK, Lichtin AE, Advani AS, Sobecks RM, Cinalli T, Dodd K, Ai J, Saunthararajah Y, Kalaycio M, Stein BL, Sekeres MA, Tiu RV (2013) Modified dose escalation of ruxolitinib: a feasible therapeutic approach in the management of myelofibrosis [abstract]. Blood 122:1586

85.

Harrison CN, Gisslinger B, Miller CB, Kiladijan JJ, Atienza E, Stalbovskaya V, Sirulnik A, Al-Ali HK, Barosi G, Mc Mullin MF, Verstovsek S, Vannucchi AM (2012) Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 × 10⁹/L and 99 × 10⁹/L [abstract]. ASH Annual Meeting Abstracts 120:177

86.

McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jakel N, Sirulnik A, McQuity M, Stalbovskaya V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al- Ali HK (2012) The use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF) [abstract]. Blood 120:2838

87.

Tefferi A, Thiele J, Vardiman JW (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115:3842–3847. doi:10.1002/cncr.24440 PubMedCrossRef

88.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Müllauer L, Finazzi G, Carobbio A, Gianatti A, Ruggeri M, Nichele I, D’Amore E, Rambaldi A, Tefferi A (2012) Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119:2239–2241. doi:10.1182/blood-2011-11-393819 PubMedCrossRef

89.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, for the CYTO-PV Collaborative Group (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22–33. doi:10.1056/NEJMoa1208500 PubMedCrossRef

90.

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881. doi:10.1038/leu.2013.163 PubMedPubMedCentralCrossRef

91.

Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114–124. doi:10.1056/NEJMoa035572 PubMedCrossRef

92.

Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29:3907–3913. doi:10.1200/JCO.2011.36.0792 PubMedCrossRef

93.

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148:961–963. doi:10.1111/j.1365-2141.2009.08019.x PubMedCrossRef

94.

Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065–3072. doi:10.1182/blood-2008-03-143537 PubMedCrossRef

95.

Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418–5424. doi:10.1200/jco.2009.23.6075 PubMedCrossRef

96.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120:513–520. doi:10.1002/cncr.28441 PubMedCrossRef

97.

Verstovsek S, Kiladjian J-J, Griesshammer M, Masszi T, Durrant STS, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa RA, He S, Jones M, Garrett WM, Li J, Pirron U, Lawniczek T, Vannucchi AM Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial [abstract 7026]. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 29–June 2, 2015

98.

Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426–435. doi:10.1056/NEJMoa1409002 PubMedPubMedCentralCrossRef

99.

Kiladjian J-J, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Cazzola M, Besses C, Blau I, Mesa R, Jones MM, He S, Zhen H, Li J, Francillard N, Habr D, Verstovsek S (2015) Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial [S447]. Paper presented at the 20th Congress of the European Hematology Association, Vienna, Austria, June 11–14, 2015

100.

Chen X, Shi JG, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, Punwani NG, Williams WV, Yeleswaram S (2014) Pharmacokinetics and pharmacodynamics of orally-administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clin Pharmacol Drug Dev 3:34–42PubMedCrossRef

101.

Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192–1202. doi:10.1182/blood-2013-03-484642 PubMedCrossRef

102.

Barosi G, Campanelli R, Fois G, Poletto V, Villani L, Bonetti E, Catarsi P, Rosti V, Massa M (2013) Decrease of T regulatory cells in patients with myelofibrosis receiving ruxolitinib [abstract]. Blood 122:4057

103.

Massa M, Rosti V, Campanelli R, Fois G, Barosi G (2014) Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia 28:449–451. doi:10.1038/leu.2013.296 PubMedCrossRef

104.

Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuk F, Kröger N (2014) JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 28:1736–1738. doi:10.1038/leu.2014.86 PubMedCrossRef

105.

Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369:197–198. doi:10.1056/NEJMc1302135 PubMedCrossRef

106.

Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G (2014) Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28:225–227. doi:10.1038/leu.2013.235 PubMedCrossRef

107.

Tong LX, Jackson J, Kerstetter J, Worswick SD (2014) Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol 70:e59–e60. doi:10.1016/j.jaad.2013.09.035 PubMedCrossRef

108.

Hopman RK, Lawrence SJ, Oh ST (2014) Disseminated tuberculosis associated with ruxolitinib. Leukemia 28:1750–1751. doi:10.1038/leu.2014.104 PubMedCrossRef

109.

Punwani N, Yeleswaram S, Chen X, Bowman J, Soloviev M, Williams W (2014) Evaluation of the effect of ruxolitinib on cardiac repolarization: a thorough QT study. Clin Pharmacol Drug Dev 3:207–214. doi:10.1002/cpdd.90 PubMedCrossRef

110.

Desterke C, Martinaud C, Ruzehaji N, Le Bousse-Kerdiles MC (2015) Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. Mediators Inflamm 2015:415024. doi:10.1155/2015/415024 PubMedPubMedCentralCrossRef

111.

Mascarenhas J (2015) Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis. Hematology Am Soc Hematol Educ Program 2015:329–339. doi:10.1182/asheducation-2015.1.329 PubMed

Title: Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Authors: Jeffrey C. Bryan
Srdan Verstovsek
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3012-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma

Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma

A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors

Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer